Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study
Ann R. Falsey, Tessa Hosman, Arangassery Rosemary Bastian, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 9, pp. 1015-1024
Closed Access | Times Cited: 12

Showing 12 citing articles:

Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development
Pius I. Babawale, Iván Martínez-Espinoza, Andrew Mitchell, et al.
Pathogens (2025) Vol. 14, Iss. 2, pp. 104-104
Open Access
The seroprevalence of adenoviruses since 2000
Lingling Hong, Jiashun Li, Weikai Zeng, et al.
Emerging Microbes & Infections (2025)
Open Access
Progress on Respiratory Syncytial Virus Vaccine Development and Evaluation Methods
Lie Deng, H. Cao, Guichang Li, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 304-304
Open Access
Vaccines for Respiratory Viruses—COVID and Beyond
Kalpana Rajanala, Arun Kumar Upadhyay
Vaccines (2024) Vol. 12, Iss. 8, pp. 936-936
Open Access | Times Cited: 2
A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study
Elke Jordan, Victoria A. Jenkins, Günter Silbernagl, et al.
Vaccine (2024) Vol. 42, Iss. 26, pp. 126427-126427
Closed Access | Times Cited: 2
Efficacy, Safety, and Immunogenicity of the AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over Three RSV Seasons: A Randomized Trial
Michael G. Ison, Alberto Papi, Eugene Athan, et al.
(2024)
Closed Access | Times Cited: 2
The long-term efficacy of a respiratory syncytial virus vaccine for older adults
Charles Sande
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 9, pp. 941-942
Closed Access | Times Cited: 1
Advocating for inclusive respiratory syncytial virus vaccine trials to address health disparities
Zitta Barrella Harboe, Omid Rezahosseini, Thea Kølsen Fischer
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 8, pp. e479-e479
Closed Access | Times Cited: 1
Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial
Archana Jastorff, Efi Gymnopoulou, José A. Salas, et al.
Vaccine (2024) Vol. 43, pp. 126514-126514
Open Access | Times Cited: 1
Immune Responses to Respiratory Syncytial Virus Vaccines: Advances and Challenges
Gabriela Souza da Silva, Sofia Giacomet Borges, Bruna Bastos Pozzebon, et al.
Microorganisms (2024) Vol. 12, Iss. 11, pp. 2305-2305
Open Access
Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue
Qianqian Li, Huan Li, Zhihua Li, et al.
MedComm (2024) Vol. 5, Iss. 12
Open Access
Scenario projections of RSV hospitalizations averted due to new immunization programs in King County, Washington, October 2023 to May 2025
C. Hansen, Lawrence Lee, Samantha J. Bents, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1

Scroll to top